AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have received an average rating of “Moderate Buy” from the twelve research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $82.00.

ANAB has been the subject of a number of analyst reports. Piper Sandler dropped their price objective on AnaptysBio from $95.00 to $93.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Leerink Partners set a $90.00 target price on AnaptysBio in a research note on Friday, May 15th. Wall Street Zen cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Zacks Research lowered AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Finally, UBS Group upped their price target on AnaptysBio from $60.00 to $76.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th.

AnaptysBio Price Performance

ANAB opened at $55.47 on Tuesday. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -51.36 and a beta of 0.72. The firm has a 50 day simple moving average of $57.52 and a 200 day simple moving average of $58.19. AnaptysBio has a fifty-two week low of $11.40 and a fifty-two week high of $72.36.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). The business had revenue of $25.56 million for the quarter, compared to analysts’ expectations of $18.86 million. As a group, analysts expect that AnaptysBio will post -1.35 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ANAB. Persistent Asset Partners Ltd acquired a new stake in AnaptysBio in the second quarter worth $39,000. Smartleaf Asset Management LLC grew its holdings in shares of AnaptysBio by 5,864.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 821 shares during the period. Larson Financial Group LLC grew its holdings in shares of AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 473 shares during the period. Tower Research Capital LLC TRC increased its position in shares of AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,377 shares in the last quarter. Finally, Osaic Holdings Inc. increased its position in shares of AnaptysBio by 11,630.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 2,326 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.